RxSight Inc. Common Stock
RXSTUnited States
5 filed reports · 258 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 849 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 765 | Dec 2025 |
Financial data
258 concepts · 1,614 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial257 concepts · 1,574 facts · Dec 2023 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Balance at beginning of period13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Shares issued for the exercise of stock options and vesting of restricted stock units, Amount13 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest and other income12 · Dec 2023 to Jun 2026
- Interest expense (US GAAP)12 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
- Accretion amortization of discounts and premiums investments11 · Dec 2023 to Jun 2026
- Capital expenditures incurred but not yet paid11 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
- Deferred revenue additions11 · Dec 2023 to Jun 2026
- Deferred revenue revenue recognized111 · Dec 2023 to Jun 2026
Product1 concepts · 40 facts · Dec 2023 to Jun 2026
- Revenue40 · Dec 2023 to Jun 2026
Segments
40 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service5 members · 40 facts
- LDD12 · Dec 2023 to Jun 2026
- Rxlal12 · Dec 2023 to Jun 2026
- Service Warranty Service Contracts And Accessories12 · Dec 2023 to Jun 2026
- License And Collaboration Revenue2 · Jun 2025 to Jun 2026
- Product2 · Jun 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1May 9, 2026
- FY2025 Q4Feb 25, 2026
- FY2025 Q3Nov 5, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.